Laverock Therapeutics
Laverock Therapeutics is a pioneering biotech company focused on developing programmable, gene-silencing advanced therapies for major diseases. With a powerful platform technology called GEiGS®, they aim to create safer, more effective, and accessible treatments by harnessing natural gene regulatory mechanisms. The company is committed to innovation, collaboration, and addressing high unmet clinical needs through its pipeline and partnerships.
Industries
Nr. of Employees
small (1-50)
Laverock Therapeutics
Products
Programmable gene control platform
Platform technology that redirects endogenous small RNA activity to provide programmable, tunable, multiplex and stable gene silencing for therapeutic and non-therapeutic applications.
Preclinical T-cell and macrophage therapeutic programmes
In-house preclinical programmes engineering T cells and macrophages with tumour-microenvironment- and phenotype-responsive gene control for oncology applications.
iPSC-derived product development platform
Approach and workflows to produce iPSC-derived therapeutic products with cell-identity linked gene control to ensure silencing occurs in terminally differentiated target cell types.
Programmable gene control platform
Platform technology that redirects endogenous small RNA activity to provide programmable, tunable, multiplex and stable gene silencing for therapeutic and non-therapeutic applications.
Preclinical T-cell and macrophage therapeutic programmes
In-house preclinical programmes engineering T cells and macrophages with tumour-microenvironment- and phenotype-responsive gene control for oncology applications.
iPSC-derived product development platform
Approach and workflows to produce iPSC-derived therapeutic products with cell-identity linked gene control to ensure silencing occurs in terminally differentiated target cell types.
Services
Partnerships for platform integration and outlicensing
Collaborative and outlicensing opportunities to integrate programmable gene control technologies into partner therapeutic or non-therapeutic programmes.
Custom RNA design and screening services
Design and experimental screening of silencing RNA constructs tailored to cell-type miRNA profiles and target genes using pooled and arrayed high-throughput workflows.
Cell engineering and cell line development services
Automated generation of pooled and clonal cell lines, genotyping and functional characterisation to support discovery and preclinical workflows.
Biomanufacturing engineering consultation
Application of stable and tunable silencing for metabolic engineering of production cell lines to optimise yield and product quality.
Partnerships for platform integration and outlicensing
Collaborative and outlicensing opportunities to integrate programmable gene control technologies into partner therapeutic or non-therapeutic programmes.
Custom RNA design and screening services
Design and experimental screening of silencing RNA constructs tailored to cell-type miRNA profiles and target genes using pooled and arrayed high-throughput workflows.
Cell engineering and cell line development services
Automated generation of pooled and clonal cell lines, genotyping and functional characterisation to support discovery and preclinical workflows.
Biomanufacturing engineering consultation
Application of stable and tunable silencing for metabolic engineering of production cell lines to optimise yield and product quality.
Expertise Areas
- Programmable gene silencing and RNAi repurposing
- Computational design of silencing RNAs
- High-throughput RNA screening and assay development
- Automated cell engineering and clonal line development
Key Technologies
- Gene editing–induced redirection of endogenous miRNA pathways
- Computational sRNA design platform
- Pooled high-throughput RNA screening
- Automated cell engineering workflows